Genprex Partners with MD Anderson to Identify Biomarkers for Reqorsa Gene Therapy
Event summary
- Genprex has signed a Sponsored Research Agreement with UT MD Anderson to study biomarkers TROP2 and PTEN that may predict patient response to Reqorsa Gene Therapy.
- The research aims to refine patient selection strategies for Acclaim-1 and Acclaim-3 clinical trials for NSCLC and SCLC.
- Acclaim-1 Phase 1 results showed one patient maintained a partial response for over 42 months with REQORSA and Tagrisso.
- Acclaim-3 Phase 1 results included one patient achieving an unconfirmed partial remission after 24 cycles of REQORSA and Tecentriq.
The big picture
Genprex's collaboration with MD Anderson underscores the growing emphasis on precision oncology, where biomarker-driven patient selection could improve treatment efficacy and streamline clinical development. The company's focus on refining its lung cancer trials aligns with broader industry trends toward personalized medicine, particularly in oncology where unmet medical needs remain significant. The strategic partnership also highlights the importance of academic-industry collaborations in advancing gene therapy research.
What we're watching
- Biomarker Validation
- Whether TROP2 and PTEN biomarkers can reliably predict patient response to Reqorsa, potentially enhancing clinical trial outcomes.
- Clinical Trial Progress
- The pace at which Acclaim-1 and Acclaim-3 trials advance, particularly in the Phase 2 expansion portions.
- Regulatory Pathway
- How the biomarker research impacts Genprex's regulatory strategy for Reqorsa, given the FDA's Fast Track and Orphan Drug designations.
Related topics